IDO1 and melanoma: Although IDO has been associated with resistance to immunotherapy, the concomitant use of an IDO inhibitor with pembrolizumab (anti-PD1 antibody) in patients with unresectable melanoma has not provided benefit due to the establishment of immunosuppressive compensation by induction of TDO expression [158,159].